Therapeutic agents for steroid-refractory immune checkpoint inhibitor-related myocarditis: a narrative review.

ABSTRACT:

Background and objective

Immune checkpoint inhibitors (ICIs) have become one of the cornerstones of current oncology treatment, and immune checkpoint inhibitor-related myocarditis (IRM) is the most fatal of all immune checkpoint inhibitor-related adverse events (irAEs). Methylprednisolone pulse therapy (500-1,000 mg/day) is the initial treatment for IRM recommended by almost all relevant guidelines. However, subsequent treatment regimens remain unclear for patients who do not respond to methylprednisolone pulse therapy (who are defined as steroid-refractory patients). We propose a potential treatment approach for steroid-refractory IRM.

Methods

The PubMed and the Cochrane Library databases were searched using keywords related to IRM. Relevant English-language articles publis

SUBMITTER: Wang Y 

PROVIDER: S-EPMC11384453 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature